Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in secondary progressive multiple sclerosis
NL-OMON39952Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of natalizumab in secondary-progressive multiple sclerosis (SPMS), sponsored by Biogen. Primary endpoints: Confirmed disability progression status at study end, Confirmed progression by EDSS and 3 more. Started Jul 2012; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON39952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39952.